BMO Capital analyst Evan Seigerman downgraded Merus (MRUS) to Market Perform from Outperform with a price target of $97, down from $110, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm views the deal as a “significant positive” for shareholders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus downgraded to Equal Weight from Overweight at Barclays
- Merus downgraded to Market Perform from Outperform at LifeSci Capital
- Balanced Hold Rating on Genmab’s Acquisition of Merus Amid Valuation and Strategic Fit Concerns
- Merus downgraded to Neutral from Buy at Guggenheim
- Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration